IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Matthew Wecksell who wrote (262)	12/29/1996 12:02:00 PM
From: Brad C. Dunlap	of 1762

Hi Matt, I can tell you that there have been no analyst comments or any news on Idec that would account for this past weeks action. However, when Coulter Pharmaceuticals[competitor] released their preliminary prospectus that was greatly anticipated and answered alot of unanswered questions. Both the release of Coulter's info and Idec's price movement this past week were simultaneous. Back in June and July of this year when Idec went from a high of 32 5/8 down to 14 was due to a sharp 20% pullback in the nasdaq and was very much amplified by Coulter's presentation at the ASCO conference. As a result of this conference much weakness was created in the price of Idec's stock since this was the first that Coulter's phase I/II results were made public. A minor competitive feud has developed between both firms and I can personally assure you that some large institutional investors have been watching both companies very closely and this is being reflected in Idec's stock.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next